Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

L. Castagnoli, G. C. Ghedini, A. Koschorke, T. Triulzi, M. Dugo, P. Gasparini, P. Casalini, A. Palladini, M. Iezzi, A. Lamolinara, P. L. Lollini, P. Nanni, C. Chiodoni, E. Tagliabue, S. M. Pupa

Research output: Contribution to journalArticle

Abstract

We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2-1 and WTHER2-2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29 High /CD24 + /SCA1 Low cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2-1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2- vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7-d16 and T47D-d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.

Original languageEnglish
Pages (from-to)1721-1732
Number of pages12
JournalOncogene
Volume36
Issue number12
DOIs
Publication statusPublished - Mar 23 2017

Fingerprint

Breast Neoplasms
Transgenic Mice
Anoikis
Spinocerebellar Ataxias
Neoplasms
Aldehyde Dehydrogenase
Epithelial-Mesenchymal Transition
MCF-7 Cells
Tumor Cell Line
Transducers
Genes
Carcinogenesis
Staining and Labeling

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. / Castagnoli, L.; Ghedini, G. C.; Koschorke, A.; Triulzi, T.; Dugo, M.; Gasparini, P.; Casalini, P.; Palladini, A.; Iezzi, M.; Lamolinara, A.; Lollini, P. L.; Nanni, P.; Chiodoni, C.; Tagliabue, E.; Pupa, S. M.

In: Oncogene, Vol. 36, No. 12, 23.03.2017, p. 1721-1732.

Research output: Contribution to journalArticle

Castagnoli, L, Ghedini, GC, Koschorke, A, Triulzi, T, Dugo, M, Gasparini, P, Casalini, P, Palladini, A, Iezzi, M, Lamolinara, A, Lollini, PL, Nanni, P, Chiodoni, C, Tagliabue, E & Pupa, SM 2017, 'Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer', Oncogene, vol. 36, no. 12, pp. 1721-1732. https://doi.org/10.1038/onc.2016.338
Castagnoli, L. ; Ghedini, G. C. ; Koschorke, A. ; Triulzi, T. ; Dugo, M. ; Gasparini, P. ; Casalini, P. ; Palladini, A. ; Iezzi, M. ; Lamolinara, A. ; Lollini, P. L. ; Nanni, P. ; Chiodoni, C. ; Tagliabue, E. ; Pupa, S. M. / Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. In: Oncogene. 2017 ; Vol. 36, No. 12. pp. 1721-1732.
@article{904532492b274d7e814ffaea3cfd6c0c,
title = "Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer",
abstract = "We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2-1 and WTHER2-2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29 High /CD24 + /SCA1 Low cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2-1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2- vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7-d16 and T47D-d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.",
author = "L. Castagnoli and Ghedini, {G. C.} and A. Koschorke and T. Triulzi and M. Dugo and P. Gasparini and P. Casalini and A. Palladini and M. Iezzi and A. Lamolinara and Lollini, {P. L.} and P. Nanni and C. Chiodoni and E. Tagliabue and Pupa, {S. M.}",
year = "2017",
month = "3",
day = "23",
doi = "10.1038/onc.2016.338",
language = "English",
volume = "36",
pages = "1721--1732",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

AU - Castagnoli, L.

AU - Ghedini, G. C.

AU - Koschorke, A.

AU - Triulzi, T.

AU - Dugo, M.

AU - Gasparini, P.

AU - Casalini, P.

AU - Palladini, A.

AU - Iezzi, M.

AU - Lamolinara, A.

AU - Lollini, P. L.

AU - Nanni, P.

AU - Chiodoni, C.

AU - Tagliabue, E.

AU - Pupa, S. M.

PY - 2017/3/23

Y1 - 2017/3/23

N2 - We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2-1 and WTHER2-2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29 High /CD24 + /SCA1 Low cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2-1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2- vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7-d16 and T47D-d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.

AB - We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (BC) tumorigenesis, progression and response to Trastuzumab. However, the mechanisms by which d16HER2 contributes to HER2-driven aggressiveness and targeted therapy susceptibility remain uncertain. Here, we report that the d16HER2-positive mammary tumor cell lines MI6 and MI7, derived from spontaneous lesions of d16HER2 transgenic (tg) mice and resembling the aggressive features of primary lesions, are enriched in the expression of Wnt, Notch and epithelial-mesenchymal transition pathways related genes compared with full-length wild-type (WT) HER2-positive cells (WTHER2-1 and WTHER2-2) derived from spontaneous tumors arising in WTHER2 tg mice. MI6 cells exhibited increased resistance to anoikis and significantly higher mammosphere-forming efficiency (MFE) and self-renewal capability than the WTHER2-positive counterpart. Furthermore, d16HER2-positive tumor cells expressed a higher fraction of CD29 High /CD24 + /SCA1 Low cells and displayed greater in vivo tumor engraftment in serial dilution conditions than WTHER2-1 cells. Accordingly, NOTCH inhibitors impaired mammosphere formation only in MI6 cells. A comparative analysis of stemness-related features driven by d16HER2 and WTHER2 in ad hoc engineered human BC cells (MCF7 and T47D) revealed a higher MFE and aldehyde dehydrogenase-positive staining in d16HER2- vs WTHER2-infected cells, sustaining consistent BC-initiating cell enrichment in the human setting. Moreover, marked CD44 expression was found in MCF7-d16 and T47D-d16 cells vs their WTHER2 and Mock counterparts. Clinically, BC cases from two distinct HER2-positive cohorts characterized by high levels of expression of the activated-d16HER2 metagene were significantly enriched in the Notch family and signal transducer genes vs those with low levels of the metagene.

UR - http://www.scopus.com/inward/record.url?scp=84988420073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988420073&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.338

DO - 10.1038/onc.2016.338

M3 - Article

C2 - 27641338

AN - SCOPUS:84988420073

VL - 36

SP - 1721

EP - 1732

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 12

ER -